Department of Oncology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.
Hematol Oncol Clin North Am. 2010 Feb;24(1):35-63. doi: 10.1016/j.hoc.2009.11.008.
Acute myeloid leukemia (AML) is a heterogeneous group of leukemias that result from clonal transformation of hematopoietic precursors through the acquisition of chromosomal rearrangements and multiple gene mutations. As a result of highly collaborative clinical research by pediatric cooperative cancer groups worldwide, disease-free survival has improved significantly during the past 3 decades. Further improvements in outcomes of children who have AML probably will reflect continued progress in understanding the biology of AML and the concomitant development of new molecularly targeted agents for use in combination with conventional chemotherapy drugs.
急性髓系白血病 (AML) 是一组异质性白血病,源于造血前体细胞通过获得染色体重排和多个基因突变而发生的克隆转化。由于全世界儿科癌症协作组的高度协作临床研究,过去 30 年来,无病生存率已显著提高。AML 患儿的治疗效果进一步改善可能反映出对 AML 生物学的持续深入了解,以及随之开发出的新的分子靶向药物与传统化疗药物联合使用。